- Home
- OPHC vs FBIO Comparison
OPHC vs FBIO Comparison
Compare OPHC & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- FBIO
- Stock Information
- Founded
- OPHC 2000
- FBIO 2006
- Country
- OPHC United States
- FBIO United States
- Employees
- OPHC N/A
- FBIO N/A
- Industry
- OPHC Major Banks
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- FBIO Health Care
- Exchange
- OPHC Nasdaq
- FBIO Nasdaq
- Market Cap
- OPHC 49.0M
- FBIO 39.4M
- IPO Year
- OPHC N/A
- FBIO N/A
- Fundamental
- Price
- OPHC $4.73
- FBIO $1.87
- Analyst Decision
- OPHC Hold
- FBIO Strong Buy
- Analyst Count
- OPHC 1
- FBIO 3
- Target Price
- OPHC $5.25
- FBIO $18.00
- AVG Volume (30 Days)
- OPHC 34.7K
- FBIO 658.0K
- Earning Date
- OPHC 03-07-2025
- FBIO 11-14-2024
- Dividend Yield
- OPHC N/A
- FBIO N/A
- EPS Growth
- OPHC 78.77
- FBIO N/A
- EPS
- OPHC 1.32
- FBIO N/A
- Revenue
- OPHC $34,509,000.00
- FBIO $81,501,000.00
- Revenue This Year
- OPHC N/A
- FBIO N/A
- Revenue Next Year
- OPHC N/A
- FBIO $128.63
- P/E Ratio
- OPHC $3.57
- FBIO N/A
- Revenue Growth
- OPHC 66.69
- FBIO 31.51
- 52 Week Low
- OPHC $3.89
- FBIO $1.36
- 52 Week High
- OPHC $5.90
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- OPHC 50.50
- FBIO 44.79
- Support Level
- OPHC $4.46
- FBIO $1.84
- Resistance Level
- OPHC $4.77
- FBIO $2.36
- Average True Range (ATR)
- OPHC 0.12
- FBIO 0.18
- MACD
- OPHC 0.01
- FBIO -0.03
- Stochastic Oscillator
- OPHC 56.25
- FBIO 5.77
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.